COST-EFFECTIVENESS OF AFATINIB AND ERLOTINIB AS SECOND-LINE TREATMENTS FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG IN CHINA
VALUE IN HEALTH（2017）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined